Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
General Infectious Disease
How do you utilize (1,3)-beta-D-glucan in CSF for diagnosing and monitoring non-cryptococcal CNS fungal infections?
Related Questions
Do you use CNS dosing of antibiotics for any portion of the treatment course in patients with infective endocarditis who have cerebral emboli?
When would you consider an all-oral regimen for patients with Whipple's disease instead of the typical parenteral treatment with ceftriaxone or meropenem followed by oral TMP/SMX?
What do you think about chronic suppressive therapy for HSV-2 in a patient with positive antibodies but no prior clinical outbreak?
How would you treat an asymptomatic patient with a positive Blastomyces antibody, evidence of prior granulomatous lung disease on imaging, and who may require immunosuppression in the future?
Do you recommend immunomodulating treatments such as steroids or IVIG for West Nile Virus neuroinvasive disease?
What is your preferred empiric antibiotic escalation for a patient with chorioamnionitis with worsening signs of sepsis on single agent cefoxitin?
How do you approach patients who continue to experience pruritus and ongoing concern for persistent scabies despite having completed appropriate treatment?
Do you regularly recommend an immunological workup for patients with suspected immunodeficiency or defer to immunology?
Do you routinely use cefdinir for the treatment of common infections diagnosed in the outpatient setting such as CAP, uncomplicated UTIs?
What is your approach to managing antimicrobial therapy for intra-abdominal infections to avoid unnecessary double anaerobic coverage, in light of associated risks and guidelines?
